International Journal of Pharma and Bio Sciences
ijpbs.net
editorijpbs@rediffmail.com (or) editorofijpbs@yahoo.com (or) prasmol@rediffmail.com
10.22376/ijpbs.2019.10.1.p1-12
Volume 2 Issue 1
2011 (January - March)
Linagliptin- a novel dpp-iv inhibitor
Although glycemic control is an important and effective way to prevent and minimize the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which often proves difficult to manage. Most affected patients will eventually require therapy with multiple medications in order to reach appropriate glycemic targets. The dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a relatively new class of oral medications for the treatment of type 2 diabetes, which has become widely incorporated into clinical practice. Linagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical development for the treatment of type 2 diabetes. It exhibits non-linear pharmacokinetics and shows concentrationdependent plasma protein binding to its target, DPP-4. lessThan br / greaterThan
N.Prabavathy,M.Vijayakumari,M.Minil,U.Sathiyaraj,S.Kavimani
Type 2 diabetes, DPP-4 inhibitor, non-linear pharmacokinetics, Linagliptin, DPP-4, protein binding
438-442